Dihydroorotate Dehydrogenase

ADC Related

ADC Antibody ADC Cytotoxin ADC Linker ADCs Drug-Linker Conjugates for ADC
Angiogenesis

5-alpha Reductase ALK Bcr-Abl BTK EGFR FAK FLT3 HER-2 HIF Src Syk VDA VEGFR
Anti-infection

Antibiotic Arenavirus Bacterial CMV EBV Enterovirus Filovirus Fungal Gli HBV HCV HCV Protease HIV HSV Influenza Virus Parasite RABV Reverse Transcriptase RSV SARS-CoV TMV Virus Protease
Apoptosis

Apoptosis ASK Bcl-2 Caspase c-Myc c-RET Cytohesin DAPK Ferroptosis FKBP IAP Mdm2 p53 PD-1 PD-L1 PERK PKD Ras RIP kinase ROS Survivin Thymidylate Synthase TNF Receptor TNFa TRADD
Autophagy

Autophagy LRRK2 Mitophagy OGA ULK
Cell Cycle

Antifolate APC Aurora Kinase BMI-1 CDK Chk c-Myc Eukaryotic Initiation Factor G-quadruplex HDAC HSP Kinesin LIMK Mad2 Microtubule(Tubulin) Mps1 Nucleoside Antimetabolite/Analog Nur77 p21 PAK PERK PFKFB PLK PPAR Ras Rho ROCK SRPK TOPK Topoisomerase Wee1
Cytoskeletal Signaling

Arp2 3 Complex Bcr-Abl Cardiac Myosin Dynamin Gap Junction Protein HSP Integrin Kinesin Microtubule Associated MLCK Myosin PAK TACC3 Wntbeta-catenin
DNA Damage

ATM(ATR) CRISPR(Cas9) DNA alkylator DNA Stain DNA(RNA) Synthesis GAK HDAC HSP Nucleoside Antimetabolite(Analog) OGG1 p97 PARG PARP RAD51 RNR Sirtuin SMN Telomerase Topoisomerase
Endocrinology & Hormones

5-alpha Reductase ACE Adrenergic Receptor Androgen Receptor Aromatase Estrogenprogestogen Receptor Glucocorticoid Receptor GPR Mineralocorticoid Receptor RAAS THR TSH Receptor
Epigenetics

AMPK Aurora Kinase DNA Methyltransferase Epigenetic Reader Domain EZH1 2 HDAC HIF Histone Acetyltransferase Histone Demethylase Histone Methyltransferase JAK MAT MicroRNA MLL Pim PKC Protein Arginine Deiminase Sirtuin Small Interfering RNA (siRNA) SMYD

+MORE

Dihydroorotate Dehydrogenase

Dihydroorotate dehydrogenase (DHODH) is the fourth enzyme in the de novo pyrimidine biosynthesis pathway, serving as the catalyst to oxidize the dihydroorotate to orotic acid in the biosynthesis of uridine monophosphate (UMP). Both autoimmune diseases and malaria have been known to be affected by DHODH.

DHODHs are divided into two families based on localization and the electron acceptor: While family 2 members are membrane proteins localized to the inner mitochondrial membrane, family 1 members are soluble proteins localized to the cytosol. Families 1A and 1B, which use fumarate and NAD+ as their respective electron acceptors, are further divided into families 1. Respiratory quinones are used by DHODH enzymes in family 2 as electron acceptors.

Dihydroorotate Dehydrogenase related products

Cat No.	Product Name	CAS No.	Product Description
V71993	(E/Z)-Ginkgolic acid C17:2 (ginkgolic acid C17:2)	102811-39-2	(E/Z)-Ginkgolic acid C17:2 is developed from Ginkgo biloba and targets human dihydroorotate dehydrogenase (DHODH).
V2473	AG-636	1623416-31-8	AG 636 (AG636; AG-636) is a novel,potent, reversible, selective and orally active dihydroorotate dehydrogenase (DHODH) inhibitor (IC50=17 nM) which has strong anticancer effects.
V55156	Ascochlorin A (Acremochlorin A)	2550720-02-8	Ascochlorin A is a novel and potent hDHODH inhibitor (KD = 3.29 μM) studied in triple-negative breast cancer.
V52260	CHIKV-IN-2	2361289-44-1	CHIKV-IN-2 is a potent inhibitor against chikungunya virus (CHIKV) with excellent cellular antiviral effect (EC90=270 nM) and improved liver microsomal stability.
V52180	DHODH-IN-16	2511248-11-4	DHODH-IN-16 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor (antagonist) with IC50 of 0.396 nM for human DHODH.
V71992	DHODH-IN-17	16344-26-6	DHODH-IN-17, as a 2-anilinoylnicotinic acid, is a human DHODH inhibitor (IC50=0.40 μM).
V72001	DHODH-IN-18	2685799-97-5	DHODH-IN-18 is a human DHODH inhibitor (IC50 = 0.2 nM)
V72002	DHODH-IN-21	2450341-39-4	DHODH-IN-21 (compound 19) is an orally bioactive, selective dihydrolactate dehydrogenase (DHODH) inhibitor (antagonist) with IC50 of 1.1 nM.
V71994	DHODH-IN-23	1346705-53-0	DHODH-IN-23 (Compound A) is an orally bioactive DHODH inhibitor that may be utilized in cancer-related research.
V52154	DSM502	2426616-55-7	DSM502 is a pyrrole-based inhibitor of dihydroorotate dehydrogenase (DHODH).
V52153	DSM705	2653225-38-6	DSM705 is a pyrrole-based inhibitor of dihydroorotate dehydrogenase (DHODH).
V71999	hDHODH-IN-11	2396653-34-0	hDHODH-IN-11 is a potent inhibitor of human dihydrorotamate dehydrogenase (hDHODH) with IC50 of 7.2 nM.
V79740	hDHODH-IN-13	3032611-13-2	hDHODH-IN-13 is an inhibitor (blocker/antagonist) of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 173.4 nM.
V71991	hDHODH-IN-14	881826-17-1	hDHODH-IN-14 (compound 14) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor (antagonist) with IC50 of 0.469 μM.
V71995	hDHODH-IN-8	2757405-31-3	hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with IC50 of 16 nM.
V71998	Indoluidin E	2763081-76-9	Indoluidin E selectively inhibits DHODH and inhibits cancer/tumor cell growth.
V71996	Leflunomide-d4 (Leflunomide d4)	1189987-23-2	Leflunomide-d4 is the deuterated form of Leflunomide.
V2626	ML390	2029049-79-2	ML390 is a novel potent inhibitor of human DHODH (Dihydroorotate dehydrogenase) that induces differentiation in acute myeloid leukemia (AML) with EC50 of 1.8μM, 8.8μM, 6.5μM, and 0.56μM in ER-HOX-GFP, U937, THP-1 cells and DHODH enzyme, respectively.
V4172	Orludodstat (BAY-2402234)	2225819-06-5	BAY-2402234 is a novel, potent/low-nanomolar and selective inhibitor of dihydroorotate dehydrogenase(DHODH) that has the potentialfor the treatment of myeloid malignancies.
V2242	PfDHODH-IN-2	425629-94-3	Desription: PfDHODH-IN-2, a dihydrothiophenone derivative (Compound 11), is a Novel and potent Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor with an IC50 of 1.11 µM.